• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

泛癌症基因组学时代的癌症驱动突变的实验鉴定。

Experimental identification of cancer driver alterations in the era of pan-cancer genomics.

机构信息

Molecular Mechanisms and Biomarkers Group, International Agency for Research on Cancer, World Health Organization, Lyon, France.

出版信息

Cancer Sci. 2019 Dec;110(12):3622-3629. doi: 10.1111/cas.14210. Epub 2019 Oct 31.

DOI:10.1111/cas.14210
PMID:31594033
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6890429/
Abstract

Rapidly accumulating data from large-scale cancer genomics studies have been generating important information about genes and their somatic alterations underlying cell transformation, cancer onset and tumor progression. However, these events are usually defined by using computational techniques, whereas the understanding of their actual functional roles and impact typically warrants validation by experimental means. Critical information has been obtained from targeted genetic perturbation (gene knockout) studies conducted in animals, yet these investigations are cost-prohibitive and time-consuming. In addition, the 3R principles (replacement, reduction, refinement) have been set in place to reduce animal use burden and are increasingly observed in many areas of biomedical research. Consequently, the focus has shifted to new designs of innovative cell-based experimental models of cell immortalization and transformation in which the critical cancer driver events can be introduced by mutagenic insult and studied functionally, at the level of critical phenotypic readouts. From these efforts, primary cell-based selective barrier-bypass models of cell immortalization have emerged as an attractive system that allows studies of the functional relevance of acquired mutations as well as their role as candidate cancer driver events. In this review, we provide an overview of various experimental systems linking carcinogen exposure-driven cell transformation with the study of cancer driver events. We further describe the advantages and disadvantages of the currently available cell-based models while outlining future directions for in vitro modeling and functional testing of cancer driver events.

摘要

大量癌症基因组学研究的数据积累,为细胞转化、癌症发生和肿瘤进展相关基因及其体细胞改变提供了重要信息。然而,这些事件通常是通过计算技术来定义的,而要真正理解其功能作用和影响,则需要通过实验手段来验证。通过在动物身上进行靶向遗传干扰(基因敲除)研究,已经获得了一些关键性信息,但这些研究既昂贵又耗时。此外,为了减少动物使用负担,人们提出了 3R 原则(替代、减少、优化),并在许多生物医学研究领域得到了广泛应用。因此,人们的研究重点已经转移到了新的、创新性的基于细胞的实验模型设计上,这些模型可以通过诱变损伤来引入关键的癌症驱动事件,并在关键表型检测水平上进行功能研究。在这些努力的基础上,出现了基于原代细胞的选择性障碍旁路模型,该模型可用于研究获得性突变的功能相关性及其作为候选癌症驱动事件的作用。在这篇综述中,我们概述了将致癌物暴露驱动的细胞转化与癌症驱动事件研究联系起来的各种实验系统。我们进一步描述了目前可用的基于细胞的模型的优缺点,并概述了体外癌症驱动事件建模和功能测试的未来方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8825/6890429/c709db46b63a/CAS-110-3622-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8825/6890429/c709db46b63a/CAS-110-3622-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8825/6890429/c709db46b63a/CAS-110-3622-g001.jpg

相似文献

1
Experimental identification of cancer driver alterations in the era of pan-cancer genomics.泛癌症基因组学时代的癌症驱动突变的实验鉴定。
Cancer Sci. 2019 Dec;110(12):3622-3629. doi: 10.1111/cas.14210. Epub 2019 Oct 31.
2
Modeling cancer driver events in vitro using barrier bypass-clonal expansion assays and massively parallel sequencing.使用屏障绕过-克隆扩增试验和大规模平行测序在体外模拟癌症驱动事件。
Oncogene. 2017 Oct 26;36(43):6041-6048. doi: 10.1038/onc.2017.215. Epub 2017 Jul 10.
3
Understanding oncogenicity of cancer driver genes and mutations in the cancer genomics era.在癌症基因组学时代,了解致癌基因和突变的致癌性。
FEBS Lett. 2020 Dec;594(24):4233-4246. doi: 10.1002/1873-3468.13781. Epub 2020 Apr 28.
4
Cancer driver gene discovery through an integrative genomics approach in a non-parametric Bayesian framework.在非参数贝叶斯框架下通过综合基因组学方法发现癌症驱动基因。
Bioinformatics. 2017 Feb 15;33(4):483-490. doi: 10.1093/bioinformatics/btw662.
5
Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.利用正选择和负选择信号区分癌症基因和乘客基因。
Elife. 2021 Jan 11;10:e59629. doi: 10.7554/eLife.59629.
6
Pan-cancer analysis of somatic mutations in miRNA genes.癌症中 miRNA 基因体细胞突变的泛癌分析。
EBioMedicine. 2020 Nov;61:103051. doi: 10.1016/j.ebiom.2020.103051. Epub 2020 Oct 7.
7
8
Iatrogenic endometriosis harbors somatic cancer-driver mutations.医源性子宫内膜异位症含有体瘤驱动突变。
Hum Reprod. 2019 Jan 1;34(1):69-78. doi: 10.1093/humrep/dey332.
9
An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).一种用于鉴定透明细胞肾细胞癌(ccRCC)中PBRM1截短突变新功能后果的综合基因组学方法。
BMC Genomics. 2016 Aug 22;17 Suppl 7(Suppl 7):515. doi: 10.1186/s12864-016-2906-9.
10
Identification of candidate cancer drivers by integrative Epi-DNA and Gene Expression (iEDGE) data analysis.通过整合表观遗传学 DNA 和基因表达(iEDGE)数据分析鉴定候选癌症驱动基因。
Sci Rep. 2019 Nov 15;9(1):16904. doi: 10.1038/s41598-019-52886-z.

引用本文的文献

1
Epigenetic regulation of TNNT1 in gastrointestinal cancers prognostic implications and clinical significance.TNNT1在胃肠道癌症中的表观遗传调控:预后意义及临床意义
Clin Epigenetics. 2025 Jul 4;17(1):115. doi: 10.1186/s13148-025-01928-7.
2
Machine learning optimized DriverDetect software for high precision prediction of deleterious mutations in human cancers.机器学习优化的 DriverDetect 软件,用于高精度预测人类癌症中的有害突变。
Sci Rep. 2024 Sep 30;14(1):22618. doi: 10.1038/s41598-024-71422-2.
3
Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers.

本文引用的文献

1
RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues.RNA 序列分析揭示了正常组织中的宏观体细胞克隆扩张。
Science. 2019 Jun 7;364(6444). doi: 10.1126/science.aaw0726.
2
Probing the Tumor Suppressor Function of BAP1 in CRISPR-Engineered Human Liver Organoids.在 CRISPR 基因编辑的人类肝类器官中探究 BAP1 的肿瘤抑制功能。
Cell Stem Cell. 2019 Jun 6;24(6):927-943.e6. doi: 10.1016/j.stem.2019.04.017. Epub 2019 May 23.
3
The Network of Cancer Genes (NCG): a comprehensive catalogue of known and candidate cancer genes from cancer sequencing screens.
泛癌分析揭示 RAB3B 表达与多种癌症肿瘤异质性、免疫微环境和预后的相关性。
Sci Rep. 2024 Apr 30;14(1):9881. doi: 10.1038/s41598-024-60581-x.
4
Prognostic value of mitochondrial CKMT2 in Pan-cancer and its tumor immune correlation analysis.线粒体 CKMT2 在泛癌中的预后价值及其与肿瘤免疫的相关性分析。
Sci Rep. 2024 Jan 3;14(1):342. doi: 10.1038/s41598-023-46468-3.
5
Non-Association of Driver Alterations in PTEN with Differential Gene Expression and Gene Methylation in IDH1 Wildtype Glioblastomas.PTEN 驱动改变与 IDH1 野生型胶质母细胞瘤中基因表达差异和基因甲基化的非关联性
Brain Sci. 2023 Jan 23;13(2):186. doi: 10.3390/brainsci13020186.
6
A critical review of datasets and computational suites for improving cancer theranostics and biomarker discovery.关于改善癌症治疗和生物标志物发现的数据集和计算套件的批判性回顾。
Med Oncol. 2022 Sep 29;39(12):206. doi: 10.1007/s12032-022-01815-8.
7
Pan-cancer analysis suggests histocompatibility minor 13 is an unfavorable prognostic biomarker promoting cell proliferation, migration, and invasion in hepatocellular carcinoma.泛癌分析表明,组织相容性微小13是一种不良预后生物标志物,可促进肝细胞癌中的细胞增殖、迁移和侵袭。
Front Pharmacol. 2022 Aug 15;13:950156. doi: 10.3389/fphar.2022.950156. eCollection 2022.
8
Chromatin Remodeler Smarca5 Is Required for Cancer-Related Processes of Primary Cell Fitness and Immortalization.染色质重塑因子 Smarca5 对于原代细胞活力和永生化的癌症相关过程是必需的。
Cells. 2022 Feb 25;11(5):808. doi: 10.3390/cells11050808.
9
ANXA2P2: A Potential Immunological and Prognostic Signature in Ovarian Serous Cystadenocarcinoma Pan-Carcinoma Synthesis.膜联蛋白A2假基因2:卵巢浆液性囊腺癌全癌综合分析中的一种潜在免疫及预后标志物
Front Oncol. 2022 Feb 8;12:818977. doi: 10.3389/fonc.2022.818977. eCollection 2022.
10
Identification of Novel Lung Cancer Driver Genes Connecting Different Omics Levels With a Heat Diffusion Algorithm.利用热扩散算法鉴定连接不同组学水平的新型肺癌驱动基因
Front Cell Dev Biol. 2022 Jan 26;10:825272. doi: 10.3389/fcell.2022.825272. eCollection 2022.
癌症基因网络(NCG):从癌症测序筛选中已知和候选癌症基因的综合目录。
Genome Biol. 2019 Jan 3;20(1):1. doi: 10.1186/s13059-018-1612-0.
4
Age-related remodelling of oesophageal epithelia by mutated cancer drivers.由突变的癌症驱动因子引起的食管上皮的年龄相关性重塑。
Nature. 2019 Jan;565(7739):312-317. doi: 10.1038/s41586-018-0811-x. Epub 2019 Jan 2.
5
Somatic mutant clones colonize the human esophagus with age.随着年龄的增长,体细胞突变克隆会在人体食管中定植。
Science. 2018 Nov 23;362(6417):911-917. doi: 10.1126/science.aau3879. Epub 2018 Oct 18.
6
Comprehensive Characterization of Cancer Driver Genes and Mutations.癌症驱动基因与突变的全面表征
Cell. 2018 Aug 9;174(4):1034-1035. doi: 10.1016/j.cell.2018.07.034.
7
Chromatin loop anchors are associated with genome instability in cancer and recombination hotspots in the germline.染色质环锚定与癌症中的基因组不稳定性和生殖系中的重组热点有关。
Genome Biol. 2018 Jul 30;19(1):101. doi: 10.1186/s13059-018-1483-4.
8
Mutational landscape of a chemically-induced mouse model of liver cancer.化学诱导的肝癌小鼠模型的突变全景。
J Hepatol. 2018 Oct;69(4):840-850. doi: 10.1016/j.jhep.2018.06.009. Epub 2018 Jun 26.
9
In-depth characterization of the cisplatin mutational signature in human cell lines and in esophageal and liver tumors.深入分析人细胞系和食管及肝脏肿瘤中顺铂突变特征。
Genome Res. 2018 May;28(5):654-665. doi: 10.1101/gr.230219.117. Epub 2018 Apr 9.
10
Systematic Functional Annotation of Somatic Mutations in Cancer.癌症体细胞突变的系统功能注释。
Cancer Cell. 2018 Mar 12;33(3):450-462.e10. doi: 10.1016/j.ccell.2018.01.021.